lundi 11 mai 2015

Onco Actu du 11 mai 2015

1. Biologie

Personalised cancer treatment a step closer with world's first 'living biobank' [The Guardian]

Mini-guts grown from colon cancers spark new treatment hopes [Science]

GTEx findings reveal new insights into how DNA differences influence gene activity, disease susceptibility [NIH]

3. Prévention

A healthy lifestyle before diagnosis may improve bowel cancer survival [Cancer Research UK]

4. Dépistage, diagnostic et pronostic

Screening Rates Stalled For Common Cancers [NPR]

Many Americans Aren’t Getting Cancer Screenings, Gov Says [TIME]

Cancer Screening Test Use — United States, 2013 [CDC]

4.1 Dép., diag. & prono. - Prostate

Myriad to Present New Clinical Data on Prolaris(R) at the AUA 2015 Annual Meeting [Myriad]

4.10 Dép., diag. & prono. - FDA, EMA, NICE,...

Roche Receives FDA Approval for cobas KRAS Mutation Test [Roche]

4.10 Dép., diag. & prono. - Poumon

On Medicare and Assessing the Value of Lung Cancer Screening [NY Times]

4.2 Dép., diag. & prono. - Génome

Developments in precision cancer medicine and regulatory implications [PHG Foundation]

Genomic Health to Present Multiple Oncotype DX® Studies and Positive Liquid Biopsy Results at American Urological Association Annual Meeting May 15-19 [Genomic Health]

4.9 Dép., diag. & prono. - Sein

ACP Internist: Where are we now with breast cancer screening? [ACP Internist]

5. Traitements

Statin drugs can delay prostate cancer progression in patients receiving androgen deprivation therapy, study shows [Dana-Farber Cancer Institute]

RAS proteins – common, cancer-causing, and can’t be drugged? [The Institute of Cancer Research, London]

5.2 Pharma

Genentech’s Phase III Study of Gazyva® Showed Significant Benefit in Refractory Indolent Non-Hodgkin’s Lymphoma [Genentech]

Novartis 'biosimilar' drug blocked by U.S. appeals court [Reuters]

5.2.1 Pharma - Partenariats

Plexxikon and Merck to Collaborate on Combination Study Evaluating Investigational Immuno-oncology Regimen [Merck]

5.2.2 Pharma - Fusions & Acquisitions

Gilead Sciences Acquires EpiTherapeutics [Gilead]

5.3 Traitements - FDA, EMA,...

Cancer drugs approved quickly but not to patient’s benefit: York U researcher [York University]

5.3.4 Traitements - AMM (FDA, EMA)

Novartis lung cancer drug Zykadia® gains EU approval, providing new therapy for certain patients with ALK+ NSCLC [Novartis]

Novartis says lung cancer drug Zykadia gains EU approval [Reuters]

5.5 ASCO

Pivotal data for Roche medicines in lung and blood cancers to be presented at ASCO [Roche]

5.6 ESMO

IMPAKT 2015 News: Analysis of Large Dataset Shows Improved Concordance of Local and Central HER2 Status [ESMO]

IMPAKT 2015 News: AP-2gamma Tumour Expression Is a New Biomarker for Resistance to Endocrine Therapy in Patients with Metastatic Breast Cancer [ESMO]

IMPAKT 2015 News: Outcome in Male Patients with Breast Cancer Varies According to Tumour Subtypes Based upon Receptor Expression [ESMO]

IMPAKT 2015 News: Gene Expression Signatures May Signal Clinical Activity of Palbociclib in Patients with Breast Cancer [ESMO]

IMPAKT 2015 News: Using a Biomarker for Neoadjuvant Bevacizumab Response to Guide Treatment Is Cost Effective in Breast Cancer [ESMO]

IMPAKT 2015 News: Incidence of Breast Cancer Oncogenes Higher in the PIK3K/AKT Signalling Pathway than in the MAPK Pathway [ESMO]

IMPAKT 2015 News: Constitutively Activated STAT3 May Be a Predictive Marker for Resistance to Trastuzumab in Patients with HER2 Positive Breast Cancer [ESMO]

IMPAKT 2015 News: A Circulating Tumour Cell Liquid Biopsy May Be Used for Non-Invasive Mutational Analysis in Patients with Breast Cancer [ESMO]

IMPAKT 2015 News: PI3 Kinase and CDK4/6 Inhibitors Are Highly Active in ER-Positive Breast Cancer [ESMO]

IMPAKT 2015 News: Molecular Screening of Patients with Metastatic Breast Cancer Can Be Carried-Out Across EU Countries [ESMO]

6.1 Observation

Prostate cancer survival rates in New Zealand grim [Science Media Centre]

6.10 Politiques

HCV, Cancer Drugs Added to Essential Medicines List as WHO Calls for Lower Prices [RAPS]

WHO Expert Committtee adds trastuzumab, imatinib, daclatasvir, sofosbuvir, bedaquiline and delaminid to EML [KEI]

6.11 Patients

The tattoos that turn breast cancer surgery scars into works of art [The Guardian]

Well: Living With Cancer: Becoming a Caregiver [NY Times]

6.4 Médico-éco

Health Care Forum [The Economist]

6.7.1 Bioinformatique

The Big Data Addiction—NGS Has It Bad [GEN]

6.7.2 Applis

GW Cancer Institute Develops First Free, Online, Comprehensive Training for Patient Navigators [The George Washington University]

Memorial Sloan Kettering Cancer Center “Specializes in You” with an Innovative and Personalized Digital Landscape [MSK]